The Conversation (0)
Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2017 Financial Results
Feb. 23, 2018 09:27AM PST
Pharmaceutical InvestingEmergent BioSolutions (NYSE:EBS) reported financial results for the quarter and twelve months ended December 31, 2017. As quoted in the press release: For Q4 2017, total revenues were $193.8 million, an increase of 28% as compared to 2016. The increase is primarily driven by increased product sales of $74.1 million mainly due to a $63.2 …
Emergent BioSolutions (NYSE:EBS) reported financial results for the quarter and twelve months ended December 31, 2017.
As quoted in the press release:
For Q4 2017, total revenues were $193.8 million, an increase of 28% as compared to 2016. The increase is primarily driven by increased product sales of $74.1 million mainly due to a $63.2 million increase in BioThrax sales as well as sales of products acquired in Q4 2017, partially offset by a $31.6 million reduction in contracts and grants revenue.
